



Universiteit
Leiden
The Netherlands

Pharmacogenetics of advanced colorectal cancer treatment

Pander, J.

Citation

Pander, J. (2011, June 29). *Pharmacogenetics of advanced colorectal cancer treatment*. Retrieved from <https://hdl.handle.net/1887/17746>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17746>

Note: To cite this publication please use the final published version (if applicable).



2

Pharmacogenetics of EGFR and VEGF inhibition

Jan Pander • Hans Gelderblom • Henk-Jan Guchelaar

Drug Discovery Today 2007 Dec;12(23-24):1054-60

Abstract

Even though treatment of several types of solid tumours has improved in the past few years with the introduction of the monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), response rates to these targeted therapies are modest. Pharmacogenetic factors have the potential to select patients with higher chance of response to agents that target these pathways. This review provides an overview over germ-line variations in genes that are potentially involved in the pharmacodynamics of the monoclonal antibodies cetuximab, panitumumab and bevacizumab, and which may underlie variable anti-tumour response.

The treatment of solid tumours has changed in the past five years with the introduction of monoclonal antibody (MAb) drugs targeting growth factor pathways that are critical for tumour growth and invasiveness. The epidermal growth factor receptor (EGFR) targeting MAbs cetuximab and panitumumab and the vascular endothelial growth factor (VEGF) targeting MAb bevacizumab are approved for the treatment of metastasized colorectal cancer (mCRC). Cetuximab and bevacizumab are also approved for the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) and advanced non-squamous, non-small cell lung cancer (NSCLC) respectively. These MAbs are commonly administered in combination with first-line chemotherapy, whereas monotherapy is also applied in subsequent lines of therapy. Despite overall improving cancer treatment, the addition of these MAbs to chemotherapy increases response rates by only 10-20%¹⁻³ and adverse events such as moderate to severe rash for the EGFR inhibitors and gastro-intestinal perforations and hypertension for bevacizumab are relatively common.¹⁻³ Moreover, the introduction of these MAbs has almost doubled cost of treatment.⁴


Therefore, selection of patients for treatment based on predictive factors for response, survival and/or toxicity could improve treatment success as well as cost-effectiveness. Pharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation. Whereas somatic mutations occur only in the affected organ or disease locus (tumour) and result in a different genetic composition of a tumour compared with other tissues in the body, germ-line polymorphisms have an ancestral origin and are heritable. In this review, we give an overview of heritable genetic factors that might predict drug induced anti-tumour response and toxicity of EGFR and VEGF targeting MAbs, based upon candidate genes for these pathways. Also, we give an overview of pharmacogenetic studies with drugs that target these pathways.

Epidermal growth factor (EGF) pathway

Cetuximab is a chimeric mouse/human IgG₁ type MAb, whereas panitumumab is a fully human IgG₂ type MAb. Both MAbs bind specifically to the extracellular domain of the EGFR and are competitive inhibitors of the natural ligands EGF and transforming growth factor- α (TGF α).

The small G protein k-ras, the protein kinase b-raf, and phosphoinositide 3-kinase (encoded by *KRAS*, *BRAF* and *PIK3CA* respectively) play a central role as intracellular mediators of EGFR signalling⁵, ultimately leading to induced transcription of several factors including interleukin-8 (IL8), VEGF and cyclin D1 (CD1, coded by *CCND1*). Cyclooxygenase-2 (COX2, encoded by *PTGS2*) is an upstream mediator of EGFR activity, presumably through the effect of prostaglandin E₂ (see Figure 1).

Figure 1 Simplified overview of the EGF and VEGF pathways



Abbreviations: ARNT: aryl hydrocarbon receptor nuclear translocator; braf: protein kinase b-raf; CD1: cyclin D1; COX2: cyclooxygenase 2; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; HIF1α: hypoxia inducible factor 1α; HIF1α-OH: hydroxylated hypoxia inducible factor 1α; IL8: interleukin 8; IL8RA: interleukin 8 receptor A; KDR: kinase domain receptor; kras: small G protein k-ras; PGE₂: prostaglandin E₂; PI3K/Akt: phosphoinositide 3-kinase/akt protein kinase; TGFα: transforming growth factor α; VEGF: vascular endothelial growth factor; VHL: von Hippel-Landau tumor suppressor

Heritable genetic variants in genes in the EGF pathway will be discussed below (see Table 1).

Epidermal Growth Factor Receptor (EGFR)

The first intron of the *EGFR* gene has an important regulatory function and contains a heritable polymorphic microsatellite sequence of 9 to 23 CA repeats. Most common alleles are the 16-repeat allele in Caucasians and Afro-Americans, and the 20-repeat in Asians.^{6,7} There is good to complete (93-100%) similarity of this polymorphism between normal and tumour tissue⁸⁻¹⁰, which is reassuring since the *EGFR* gene is highly sensitive to somatic alteration through loss of heterozygosity, mutations or copy number

Table 1 Overview of polymorphisms in genes that code for enzymes involved in the EGFR pathway

Enzyme (gene)	Polymorphism	Phenotype	Function	Ref	Pharmacogenetic association	Ref
EGFR (<i>EGFR</i>)	-191C>A		higher EGFR	7,13		
	-216G>T		higher EGFR	7,13	gefitinib (NSCLC): carriage of -216T allele → longer PFS	15
	(CA) ₉₋₂₃		higher EGFR for lower amount of CA-repeats	10,11	gefitinib (NSCLC): low amount of CA-repeats → higher response and TTP and PFS	9,15
	1808G>A	Arg497Lys	unknown		monotherapy cetuximab (mCRC): heterozygotes → longer PFS	18
EGF (<i>EGF</i>)	61A>G		higher EGF	16,17	monotherapy cetuximab (mCRC): simultaneous carriage of 61A and <i>CCND1</i> 870G allele → longer OS	18,28
					monotherapy cetuximab (mCRC): 61GG homozygotes → longer PFS	
COX2 (<i>PTGS2</i>)	-765G>C		lower COX2	19,20	monotherapy cetuximab (mCRC): -765CC homozygotes → longer PFS	18
IL8 (<i>IL8</i>)	-251T>A		higher IL8	25		
IL8RA (<i>CXCR1</i>)	2607G>C	Ser276Thr	unknown			
CD1 (<i>CCND1</i>)	870G>A		higher CD1	27	monotherapy cetuximab (mCRC): carriage of 870G allele → longer OS	28

alterations. A higher number of CA-repeats is associated with decreased expression of EGFR on both mRNA and protein level *in vitro*^{10,11}, but this association was not consistently found *in vivo*.^{9,12}

Two single nucleotide polymorphisms (SNPs; see glossary box) in the promoter (-216G>T and -191C>A) are both associated with increased expression of EGFR.^{7,13} A nonsynonymous SNP (1808G>A) in the extracellular domain of EGFR results in lower binding-affinity of EGF and TGF- α and attenuated growth response to these growth factors *in vitro*.¹⁴

Glossary box

- SNP (Single Nucleotide Polymorphism): a change of a single base of germ-line DNA, as compared with wild-type, which occurs in $\geq 1\%$ of the population. Because any individual carries two alleles, the SNP can be present in both alleles (homozygote), on only one allele (heterozygote) or not at all (wild-type).
- CNP (Copy Number Polymorphism): in contrast to a SNP, a CNP encompasses ≥ 1000 base pairs or more. Regarding heritability and population frequency, the definitions are the same.
- Mutation: a change in DNA that occurs either very infrequently ($\leq 1\%$ in the population), or only in an affected organ. In the latter case, the mutation is not inherited.
- Haplotype Block: SNPs are naturally inherited in neighboring clusters, which are called haplotype blocks.
- ADCC (antibody dependent cell-mediated cytotoxicity): the recognition by natural killer cells of the Fc region of an antibody after binding to the antigen, followed by killing of the antigen presenting cell.
- Prognostic factor: a marker for prognosis of a disease, not related to treatment
- Predictive factor: a marker for response to a certain treatment

Recently, two pharmacogenetic studies were published on the sensitivity of NSCLC patients to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. These studies are important examples of the utility of pharmacogenetics for EGFR inhibitors.

Han et al. reported an increased response and time to progression (TTP) for patients with ≤ 37 CA-repeats in Korean NSCLC patients, regardless of the presence of somatic mutations.⁹

Similarly, NSCLC patients of predominantly Caucasian origin, who were homozygous for two short CA-repeat alleles (defined as ≤ 16 CA-repeats per allele) had better progression free survival (PFS) compared with carriers of at least one allele with >17 CA-repeats. Also, patients who carried the -216T allele had longer PFS. Patients who

were homozygous for the short CA-repeat allele and simultaneously carrier of the -216T allele, had improved PFS and overall survival (OS).¹⁵

In line with these findings, Amador et al. reported higher sensitivity to another EGFR inhibiting TKI, erlotinib, in cell lines with ≤ 35 CA-repeats compared with cell lines with >35 repeats. Also, the authors found increased incidence of skin toxicity in gefitinib treated CRC patients with ≤ 35 CA-repeats.¹⁰

Upstream regulators of EGFR

A SNP in the 5'-UTR of the *EGF* gene (61A>G) has been associated with higher EGF protein expression *in vitro*¹⁶ and *in vivo*.¹⁷ The 61GG genotype was associated with increased PFS in mCRC patients who were treated with cetuximab monotherapy.¹⁸

A functional SNP in the promoter region of the *PTGS2* gene (-765G>C) has been associated with lower promoter activity *in vitro*¹⁹ and with lower expression of the *PTGS2* gene product, COX2 *in vivo*.²⁰ Illustrative of its function is the strong association with decreased risk of myocardial infarction and stroke for the -765C allele.²¹ Recently, an association for increased PFS for the -765CC genotype was reported in mCRC patients treated with single agent cetuximab.¹⁸

Downstream signalling

The presence of somatic mutations in *KRAS*, but not in *BRAF* and *PIK3CA*, has been associated with decreased effect of cetuximab in CRC patients^{22,23}, though not unequivocally.²⁴ However, no reports are available on heritable polymorphisms in these genes.

A SNP in the 5'-UTR of the *IL8* gene (-251T>A) has been associated with increased IL8 production.²⁵ The IL8 receptor alpha, IL8RA (encoded by the gene *CXCR1*) contains a nonsynonymous SNP in exon 2 (2607G>C)²⁶, whose function remains unclear. A SNP in the *CCND1* gene (870G>A) has been associated with higher expression of CD1.²⁷

Zhang et al. investigated whether there was an association for the polymorphisms in the *CCND1* (870A>G), *PTGS2* (-765G>C), *EGF* (61A>G), *EGFR* (1808G>A and CA-repeats), *IL8* (-251T>A) and *VEGF* (+936C>T) genes with the effect of cetuximab given as a single agent in advanced CRC patients.²⁸ Homozygotes for the *CCND1* 870A allele had a shorter OS compared with carriers of the 870G allele.²⁸ In combined analysis, patients who carried both a *CCND1* 870G allele and an *EGF* 61A allele had longer OS, whereas the other polymorphisms were not associated with survival.²⁸ These results, though valuable, need to be interpreted with care, as this was an exploratory study. The fact that seven different polymorphisms were analyzed in a small population raises the

probability of false positive associations. However, together with the other association studies of the EGF pathway, these findings provide an important starting point for adequately powered confirmation studies.

Vascular endothelial growth factor (VEGF) pathway

Bevacizumab is a humanized IgG₁ type MAb directed against soluble VEGF, one of the key moderators in angiogenesis, which is thought to be important for tumour growth and invasiveness.²⁹ VEGF exerts its pro-angiogenic effect via VEGF receptor-2, a tyrosine kinase receptor that is also referred to as kinase insert domain receptor (KDR). Transcription of VEGF is regulated by hypoxia inducible factor-1 α (HIF1 α) (see Figure 1).

To date, five functional SNPs in the 5' and 3' regions of the *VEGF* gene have been described (Table 2).³⁰⁻³²

The variant alleles of the -1154G>A and +936C>T SNPs are associated with lower VEGF production³²⁻³⁵, whereas the variant allele of the -460C>T SNP results in increased promoter activity.³⁶ There is less agreement on the functionality of the -2578C>A and +405G>C SNPs, as both increased as decreased VEGF production have been reported.^{31,34,35,37}

It must be noted though that the above mentioned SNPs are inherited in clusters in so called haplotype blocks (see glossary box).^{31,35,36,38-41} It is likely that only one SNP is truly functional with regard to VEGF expression, whereas the others are merely proxies for this one. This truly causal SNP, however, has so far not been identified.

There are several nonsynonymous SNPs in the coding region of the *KDR* gene (see: <http://www.ncbi.nlm.nih.gov/projects/SNP>). Nonetheless, only functionality of a CA-repeat polymorphism in intron 2 of the *KDR* gene (+4422(AC)₁₁₋₁₄) has been determined. The 11-repeat polymorphism results in higher promoter activity *in vitro*.⁴² Even though the 11- and 12-repeat alleles were most common in the Japanese population, the allele frequencies in other populations are unknown.

The nonsynonymous SNP 1772C>T in the gene encoding HIF1 α (*HIF1A*) has been associated with increased expression of HIF1 α .⁴³⁻⁴⁵ The enzyme coded by the variant allele is also less sensitive to hydroxylation dependent degradation⁴⁶, which results in further increased protein levels. Another nonsynonymous SNP (1790G>A) in the *HIF1A* gene has also been associated with increased HIF1 α expression.⁴³

As these SNPs result in increased abundance of the HIF1 α protein, it is expected that the SNPs ultimately result in increased VEGF expression (see Figure 1). The relationship

Table 2 Overview of polymorphisms in genes that code for enzymes involved in the VEGF pathway

Enzyme (gene)	Polymorphism	Phenotype	Function	Ref
VEGF (<i>VEGF</i>)	-2578C>A		lower or higher VEGF	34,35
	-1154G>A		lower VEGF	34,35
	-460C>T		increased promoter activity	36
	+405G>C		lower or higher VEGF	31,34,37
	+936C>T		lower VEGF	32,33
KDR (<i>KDR</i>)	+4422(AC) ₁₁₋₁₄		11 CA repeats higher promoter activity than 12 CA repeats	42
HIF1 α (<i>HIF1A</i>)	1772C>T	Pro582Ser	higher HIF1 α	43-46
	1790G>A	Ala588Thr	higher HIF1 α	43

between the *HIF1A* SNPs and VEGF mRNA levels has been demonstrated, whereas no relationship with VEGF protein expression was found.^{45,47}

ARNT is most commonly described as a subunit of aryl hydrocarbon receptor (AHR), which induces transcription of the cytochrome P450 isozyme CYP1A1 in response to exogenous stimuli such as cyclic aromatic hydrocarbons from cigarette smoke. As part of a dimer with HIF1 α , ARNT induces VEGF transcription. Genetic variation of the ARNT gene may therefore be of importance for VEGF production. However, to date no functional polymorphisms in the *ARNT* gene have been described.

Up to now, no pharmacogenetic studies have been published for agents that target the VEGF pathway. The publication of these studies is eagerly awaited, as they will provide a foundation for further, hypothesis testing research for this pathway.

Polymorphisms for MAbs in general

The plasma half-life of MAbs is generally relatively long: the half life of bevacizumab (20 days) is similar to that of endogenous IgG₁, whereas the half life of cetuximab and panitumumab is 70-100 hours and 7.5 days respectively. The shorter half life of the latter MAbs can in part be explained by internalization and degradation of the receptor-MAb complex after binding. It is postulated that antibodies of the IgG type, such as bevacizumab, are protected from degradation by the neonatal Fc receptor (FcRn, coded by *FCGR2*).⁴⁸

Sachs et al. recently described a variable number of tandem repeats (VNTR) within the promoter of the *FCGRT* gene consisting of five different alleles with one to five repeats (VNTR 1-5).⁴⁹ The allele frequencies of VNTR2 and VNTR3 were 0.075 and 0.92 respectively in Caucasians. The VNTR3 allele was associated with higher FcRn expression both *in vitro* and *in vivo*. Also, binding of IgG was higher among VNTR3 homozygotes compared with VNTR2/VNTR3 heterozygotes.⁴⁹ Possibly, individuals carrying the VNTR3 allele have prolonged plasma half-life of bevacizumab, and even increased response.

Cetuximab is a competitive inhibitor of EGFR, which results in decreased utilization of this pathway. As cetuximab is of the IgG₁ type, it is likely that antibody dependent cell-mediated cytotoxicity (ADCC) also plays a role in its mechanism of action. The Fc region of the antibody can be recognized by Fcγ-receptors on cytotoxic immune effector cells such as natural killer cells and macrophages. Two activating Fcγ-receptors are CD16A and CD32A (encoded by respectively *FCGR3A* and *FCGR2A*) are polymorphic (see table 3).

A SNP in the *FCGR3A* gene (559T>G; Phe158Val) has been studied since the early 1990's. IgG₁ binding is higher for the 158Val allele, which results in increased activation of ADCC but not in altered expression.^{50,51} Also, the affinity of the IgG₁-type MAb against CD20 expressing B cells, rituximab, was highest for the 158Val allele.⁵² It is therefore not surprising that response and PFS to rituximab in follicular lymphoma was higher for homozygotes of the 158Val allele, compared with carriers of the 158Phe allele.^{53,54} This SNP was not associated with clinical response to another IgG₁ MAb against TNFα, infliximab, in Crohn's disease, but increased biological response (decrease in C-reactive protein) was associated with the 158Val allele.^{55,56}

Even though the function of a SNP in the *FCGR2A* gene (535A>G; His131Arg) with regard to IgG, has not been established, an association with worse response and PFS to rituximab in follicular lymphoma was found.⁵⁴ However, this association was not confirmed by another study.⁵³

Very recently, Zhang et al. showed that mCRC patients treated with cetuximab monotherapy, who were homozygous for either the *FCGR2A* 131Arg or *FCGR3A* 158Val allele had shorter PFS and decreased response.⁵⁷ The reason for this result, which for *FCGR3A* is opposite to what would be expected, is not known. A possible explanation is that copy number polymorphism (CNP) (see next paragraph) at the locus of *FCGR3A* plays a role. This, however, has not been investigated. It is also probable that this finding is a false positive discovery, since not only these two genotypes have been investigated, but also seven others in a previous analysis of the data.²⁸

Even though ADCC does not play a role for bevacizumab, it is likely that its effect is modified by similar mechanisms.

Table 3 Overview of polymorphisms in genes that code for enzymes involved in the mechanism of action of IgG type monoclonal antibodies

Enzyme (gene)	Polymorphism	Phenotype	Function	Ref	Pharmacogenetic association	Ref
FcRn (<i>FCGRT</i>)	VNTR1-5		VNTR3 higher FcRn than VNTR2	⁴⁹		
FcγR2A (<i>FCGR2A</i>)	535A>C	His131Arg	unknown		rituximab (lymphoma): carriage of 131Arg allele → lower response and PFS cetuximab (mCRC): 131Arg homozygote → lower response and PFS	^{54,57}
FcγR3A (<i>FCGR3A</i>)	559T>G	Phe158Val	higher affinity for IgG ₁	^{50,51}	rituximab (lymphoma): carriage of 158Phe allele → lower response and PFS infliximab (mCrohn): 158Val allele → increased biological response cetuximab (mCRC): 158Val homozygote → lower response and PFS	^{53,57}

Copy number polymorphisms

An interesting novel field of pharmacogenetic research includes heritable variation of copy number of DNA segments of 1 kb or larger of the genome.⁵⁸ Analogous to the definition of a SNP, a CNP is a structural variant that occurs at a frequency of >1% in the population. Since the first whole genome array studies of this phenomenon were published in 2004^{59,60}, an open-access online database has been developed in which structural variations of the human genome are assembled^{60,61} (see: <http://projects.tcag.ca/variation>).

Several studies have demonstrated that increased intratumoral EGFR copy number in advanced CRC patients is associated with effectiveness of cetuximab.^{22,24,62} However, it must be noted that this is a somatic phenomenon, which is probably involved in the aetiology of the tumour. In the Database of Genomic Variants, there are no CNPs on the EGFR locus. Also, no CNPs are reported at the loci that cover the *TGFA*, *IL8*, *CXCR1*, *BRAF*, *KRAS*, *PIK3CA*, *PTGS2*, *VEGF*, *KDR*, *HIF1A* or *ARNT* genes. There is an infrequent CNP in the *EGF* gene (one reference to loss of the locus in 36 subjects), but CNPs on the locus that covers the *CCND1* gene occurs in 6 of 95 subjects. Also, the locus that contains the *FCGRT* gene shows heritable loss at a frequency of approximately 0.26. There is also considerable CNP covering the *FCGR2A* and *FCGR3A* genes, with equal amount of gain and loss of this locus. Illustrative of the influence of copy number variation was recently published, showing that copy number variation of the *FCGR2A* and *FCGR3A* containing region (that also contains the *FCGR3B* gene encoding CD16B) was associated with susceptibility to systemic autoimmune diseases.⁶³

Discussion

It is accepted that germ-line polymorphisms (both SNPs and CNPs) have the potential to predict outcome of therapy. Predicting outcome of therapy with cetuximab, panitumumab and bevacizumab is especially warranted, as response rates are moderate, with possible serious adverse events, at high financial cost. In this review, we give an overview of studies on polymorphisms in candidate genes in the EGF and VEGF pathways.

To date, only few small studies have shown an association of genetic polymorphisms in genes of the EGF pathway with response to EGFR targeting therapies (see Table 1), whereas studies for the VEGF pathway are thus far lacking.

However, these studies do not provide sufficient evidence to routinely genotype patients before applying these therapies. The associations need to be confirmed in one or more sufficiently powered prospective studies first. A requirement for these studies is the presence of a control group without the treatment of interest. Only then

a distinction between predictive and prognostic factors (see glossary box) can be established. This latter point is of great importance, because numerous studies have shown an association of polymorphisms within genes in the EGF and VEGF pathways with the risk and progression of several types of cancer.⁶⁴

Based upon these considerations and available studies, the predictive value of *FCGR2A*, *FCGR3A*, *EGF* and *CCND1* genotyping should be investigated prospectively for cetuximab in cases and controls. For bevacizumab and panitumumab, hypothesis generating association studies, based upon the candidate genes in this review, are required for further research.

In any pharmacogenetic association study, confounders must be carefully corrected for, in order to find independent predictive factors. Factors that need to be taken into account are gender and race, as these can impact on the response to therapy. Moreover, allele frequencies are usually different among populations. Also, care should be taken to reduce the chance of false positive associations when testing multiple genotypes. This can be accomplished by adjusting the level of significance based upon the number of genotypes tested, for example with the Bonferroni correction.

Interestingly, there appears to be major interplay between these two pathways. For example, higher intratumoral VEGF levels were associated with resistance to single agent cetuximab in mCRC patients.⁶⁵ Moreover, the combination of cetuximab and irinotecan in mCRC patients reduced circulating VEGF levels, and of these patients with the most prominent decrease of VEGF responded better as indicated by TTP and OS compared with patients who showed only a modest reduction in VEGF levels.⁶⁶ Therefore, it makes sense to look at multiple SNPs and CNPs within both pathways simultaneously.

Finally, true usefulness of a predictive marker can only be assessed with the application of a validated predictive test in a prospective setting. The test should allocate different treatment options for patients with the genotype of interest, and solid endpoints should be investigated.

In conclusion, pharmacogenetics (including germ-line SNPs and CNPs) of EGFR and VEGF inhibitors will most likely find its way to daily clinical practice, provided that the above suggestions for future research have been met.

References

1. Burtneß B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 2005;23:8646-54.
2. Hurwitz H, Fehrenbacher L, Novotny W, *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335-42.
3. Sandler A, Gray R, Perry MC, *et al.* Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542-50.
4. Garrison L, Cassidy J, Saleh M, *et al.* Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. *J Clin Oncol* 2007;25:Abstr. 4074.
5. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer* 2007;7:169-81.
6. Liu W, Innocenti F, Chen P, *et al.* Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. *Clin Cancer Res* 2003;9:1009-12.
7. Gregorc V, Cusatis G, Spreafico A, *et al.* Association of germline mutations in EGFR and ABCG2 with gefitinib response in patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2005;23:Abstr. 3022.
8. Etienne-Grimaldi MC, Pereira S, Magne N, *et al.* Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients. *Ann Oncol* 2005;16:934-41.
9. Han SW, Jeon YK, Lee KH, *et al.* Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. *Pharmacogenet Genomics* 2007;17:313-9.
10. Amador ML, Oppenheimer D, Perea S, *et al.* An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. *Cancer Res* 2004;64:9139-43.
11. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. *J Biol Chem* 1999;274:13176-80.
12. McKay JA, Murray LJ, Curran S, *et al.* Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. *Eur J Cancer* 2002;38:2258-64.
13. Liu W, Innocenti F, Wu MH, *et al.* A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. *Cancer Res* 2005;65:46-53.
14. Moriai T, Kobrin MS, Hope C, Speck L, Korc M. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. *Proc Natl Acad Sci U S A* 1994;91:10217-21.
15. Liu G, Gurubhagavatula S, Zhou W, *et al.* Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. *Pharmacogenomics J* 2008;8:129-38.
16. Shahbazi M, Pravica V, Nasreen N, *et al.* Association between functional polymorphism in EGF gene and malignant melanoma. *Lancet* 2002;359:397-401.
17. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. *Cancer Res* 2004;64:1220-3.
18. Nagashima F, Zhang W, Gordon M, *et al.* EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab (IMCL-0144). *J Clin Oncol* 2007;25:Abstr. 4129.
19. Papafili A, Hill MR, Brull DJ, *et al.* Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. *Arterioscler Thromb Vasc Biol* 2002;22:1631-6.
20. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, *et al.* Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism. *Clin Cancer Res* 2005;11:4090-6.
21. Cipollone F, Toniato E, Martinotti S, *et al.* A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *JAMA* 2004;291:2221-8.
22. Lievre A, Bachet JB, Le Corre D, *et al.* KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006;66:3992-5.
23. Di Fiore F, Blanchard F, Charbonnier F, *et al.* Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. *Br J Cancer* 2007;96:1166-9.
24. Moroni M, Veronese S, Benvenuti S, *et al.* Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. *Lancet Oncol* 2005;6:279-86.
25. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. *Thorax* 2000;55:1023-7.
26. Renzoni E, Lympany P, Sestini P, *et al.* Distribution of novel polymorphisms of the interleukin-8 and CXCR1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. *Arthritis Rheum* 2000;43:1633-40.
27. Izzo JG, Wu TT, Wu X, *et al.* Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. *J Clin Oncol* 2007;25:698-707.
28. Zhang W, Gordon M, Press OA, *et al.* Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. *Pharmacogenet Genomics* 2006;16:475-83.
29. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. *Nature* 2005;438:967-74.
30. Brogan J, Khan N, Isaac K, *et al.* Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. *Hum Immunol* 1999;60:1245-9.
31. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. *Cytokine* 2000;12:1232-5.
32. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. *J Vasc Res* 2000;37:443-8.
33. Krippel P, Langsenlehner U, Renner W, *et al.* A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. *Int J Cancer* 2003;106:468-71.
34. Koukourakis MI, Papazoglou D, Giatromanolaki A, *et al.* VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. *Lung Cancer* 2004;46:293-8.
35. Shahbazi M, Fryer AA, Pravica V, *et al.* Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. *J Am Soc Nephrol* 2002;13:260-4.
36. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. *Cancer Res* 2003;63:812-6.
37. Awata T, Inoue K, Kurihara S, *et al.* A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. *Diabetes* 2002;51:1635-9.
38. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. *Genes Immun* 2002;3:229-32.

39. Jin Q, Hemminki K, Enquist K, *et al.* Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. *Clin Cancer Res* 2005;11:3647-53.
40. Lee SJ, Lee SY, Jeon HS, *et al.* Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14:571-5.
41. Lu H, Shu XO, Cui Y, *et al.* Association of genetic polymorphisms in the VEGF gene with breast cancer survival. *Cancer Res* 2005;65:5015-9.
42. Kariyazono H, Ohno T, Khajoev V, *et al.* Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. *Pediatr Res* 2004;56:953-9.
43. Tanimoto K, Yoshiga K, Eguchi H, *et al.* Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis* 2003;24:1779-83.
44. Yamada N, Horikawa Y, Oda N, *et al.* Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. *J Clin Endocrinol Metab* 2005;90:5841-7.
45. Koukourakis MI, Papazoglou D, Giatromanolaki A, *et al.* C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. *Lung Cancer* 2006;53:257-62.
46. Fu XS, Choi E, Bublely GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. *Prostate* 2005;63:215-21.
47. Kuwai T, Kitadai Y, Tanaka S, *et al.* Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. *Int J Cancer* 2003;105:176-81.
48. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. *Proc Natl Acad Sci U S A* 1996;93:5512-6.
49. Sachs UJ, Socher I, Braeunlich CG, *et al.* A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. *Immunology* 2006;119:83-9.
50. Koene HR, Kleijer M, Algra J, *et al.* Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. *Blood* 1997;90:1109-14.
51. Wu J, Edberg JC, Redecha PB, *et al.* A novel polymorphism of Fc gammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. *J Clin Invest* 1997;100:1059-70.
52. Dall'Ozzo S, Tartas S, Paintaud G, *et al.* Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. *Cancer Res* 2004;64:4664-9.
53. Cartron G, Dacheux L, Salles G, *et al.* Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gammaRIIIa gene. *Blood* 2002;99:754-8.
54. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. *J Clin Oncol* 2003;21:3940-7.
55. Louis E, El Ghoul Z, Vermeire S, *et al.* Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. *Aliment Pharmacol Ther* 2004;19:511-9.
56. Louis EJ, Watier HE, Schreiber S, *et al.* Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. *Pharmacogenet Genomics* 2006;16:911-4.
57. Zhang W, Gordon M, Schultheis AM, *et al.* FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. *J Clin Oncol* 2007;25:3712-8.
58. Feuk L, Carson AR, Scherer SW. Structural variation in the human genome. *Nat Rev Genet* 2006;7:85-97.
59. Sebat J, Lakshmi B, Troge J, *et al.* Large-scale copy number polymorphism in the human genome. *Science* 2004;305:525-8.
60. Iafrate AJ, Feuk L, Rivera MN, *et al.* Detection of large-scale variation in the human genome. *Nat Genet* 2004;36:949-51.
61. Zhang J, Feuk L, Duggan GE, Khaja R, Scherer SW. Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. *Cytogenet Genome Res* 2006;115:205-14.
62. Lenz HJ, Van Cutsem E, Khambata-Ford S, *et al.* Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. *J Clin Oncol* 2006;24:4914-21.
63. Fanciulli M, Norsworthy PJ, Petretto E, *et al.* FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. *Nat Genet* 2007;39:721-3.
64. Hirsch FR. EGFR: a prognostic and/or a predictive marker? *J Thorac Oncol* 2006;1:395-7.
65. Vallbohmer D, Zhang W, Gordon M, *et al.* Molecular determinants of cetuximab efficacy. *J Clin Oncol* 2005;23:3536-44.
66. Vincenzi B, Santini D, Russo A, *et al.* Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. *Pharmacogenomics* 2007;8:319-27.